Additional file 2: Figure S1. of ALK alteration is a frequent event in aggressive breast cancers

Biochemical fractionation of ALK expression in breast cancer cell lines. (A) Nuclear-free cytosolic and nuclear extracts were isolated from MDA-MB231 and MCF12A cells and immunoblotted with antibodies against ALK and tubulin. (B) Relative expression of ALK was calculated using spot densitometry on cytosolic and nuclear immunoblots of MDA-MB231 and MCF12A cells. Expression of ALK was normalized with tubulin

Additional file 3: Figure S2. of ALK alteration is a frequent event in aggressive breast cancers

ALK expression in triple-negative breast cancer cell line versus normal cell line. (A) Total proteins isolated from MDA-MB231 and MCF12A cells were immunoblotted with antibodies against ALK and beta-actin. (B) Relative expression of ALK was calculated using spot densitometry on total protein immunoblots of MDA-MB231 and MCF12A cells. Expression of ALK was normalized with beta-actin

Additional file 4: Figure S3. of ALK alteration is a frequent event in aggressive breast cancers

Kaplan-Meier survival analysis for overall survival of ALK expression in breast cancer. Breast cancer patients with overexpression of ALK had reduced overall survival at 5 years compared with low expression of ALK, although not significant (p = 0.1212)

Additional file 1: Table S1. of ALK alteration is a frequent event in aggressive breast cancers

Details of primary antibodies used in the study. Details of primary antibodies used in the study including antibody clone, manufacturer and dilution used for each antibody